NCT07012993 · Phase 2 · RECRUITING
Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol
This trial is testing whether a new high-sensitivity PET scanner can produce clear brain amyloid images using 10 to 100 times less radiation than the current standard. Participants receive one of two already-approved amyloid tracers, then lie in the scanner for up to three hours. It is a Phase 2 trial, meaning researchers are still working out whether this lower-dose approach produces reliable images — it is not a treatment study.
Eligibility criteria
Inclusion Criteria: Age ≥18 years; Ability to provide informed consent and comply with study procedures; For female participants: Must not be pregnant or breastfeeding; Negative pregnancy test required for women of childbearing potential. Exclusion Criteria: Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 millisievert [mSv] total); More than four prior enrollments in this study; Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan; Pregnant or breastfeeding individuals (negative pregnancy test required); Inability to provide informed consent; Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-04-13